Association of Free Thyroxine with Progression-Free Survival in Intermediate and High Risk Differentiated Thyroid Cancer

Published: 31 May 2024| Version 1 | DOI: 10.17632/zm5br8x7y7.1
Contributors:
Raisa Ghosh,
,
,
,
,
,
,
,
,

Description

This data comprises of 3 supplementary Tables , which are part of our study. Our study is titled as : Association of Free Thyroxine with Progression-Free Survival in Intermediate and High Risk Differentiated Thyroid Cancer. This is a longitudinal cohort study which included 739 patients with intermediate and high risk thyroid cancer who have had total thyroidectomy and radioiodine treatment. They were followed for average of 8 years to calculate progression free survival and if it had any association with free T4 levels. We are only submitting 3 supplemental tables used in this study.

Files

Steps to reproduce

Supplemental Table 1: this is a table of sensitivity analysis to see if we had a good sample size to report progression free survival, using log rank test to compare 35% progression rate with each of 40%, 45%, 50%,55%,60%, and 65% respectively. Supplemental Table 2: This table is partly adapted from another table which was published previously and has been referenced in the document. The intrassay and interassay variability values were collected from the respective manufacturer assay manuals. The RRID codes were available from the antibodyregistry.org website after we deposited the information about each antibody used in the various Free T4 assays. Supplemental Table 3: This is a table showing univariate analysis to establish the association between various histological types of thyroid cancer and progression free survival. All analyses were conducted using SAS 9.4 software (SAS institute, Cary, NC) and a significance level of 0.05 was used.

Institutions

National Institute of Diabetes and Digestive and Kidney Diseases Metabolic Diseases Branch

Categories

Clinical Endocrinology

Funding

National Institute of Diabetes and Digestive and Kidney Diseases

Licence